Last updated: 2026-09-16 10:31:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Glaukos Corporation (GKOS) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NYSE. The stock is currently priced at $172.52, with a market capitalisation of $10.09B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $73.16 to $191.62. This page covers its latest market performance, valuation, price trends and company information.
$10.09B | |
$170.20 | |
$191.62 | |
$14.25 | |
$171.68 | |
100.00 | |
802.96K | |
-- | |
$191.62 | |
$73.16 | |
-- | |
-- |
Glaukos Corporation (GKOS) is trading at $172.52 in pre-market trading as of 2026-09-16 09:48:34, up 0.49% ($0.84) from the previous close of $171.68
Pre-market trading shows how investors are pricing GKOS before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Glaukos Corporation (GKOS) moved from $177.47 to $172.52, representing a decline of 2.79% ($4.95).
The stock traded between $165.43 and $185.35 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 772.71 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 83.9%
GKOS is currently trading at $172.52, placing it 83.9% of the way from its 52-week low of $73.16 to its 52-week high of $191.62. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 1094 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Glaukos Corporation (GKOS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.